HomeSGX-LISTED COMPANIESDel Monte Pacific: Strong Q1 FY2026 Growth

Del Monte Pacific: Strong Q1 FY2026 Growth

Published on

spot_img

Del Monte Pacific Limited reports a strong start to the fiscal year, with improved sales and profitability. Growth was driven by solid performance in the Philippines and international markets, particularly for fresh pineapples. The company is now fully focused on its profitable core businesses after deconsolidating its US operations.

• Philippine Powerhouse: Domestic sales soared thanks to innovative campaigns for beverages, culinary essentials, and packaged fruits

• International Acclaim: Fresh pineapple exports gained significant traction in key Asian markets, earning prestigious supplier awards

• Strategic Shift: A major change in corporate structure marks a pivotal milestone, allowing for a concentrated focus on growing the Asian business

LISTEN TO THE PODCAST BELOW:

Latest articles

Top Glove Q3 FY2026 Earnings Rise Despite Fluctuating Material Costs

Resilient Growth and Strategic Agility Top Glove Corporation has reported a remarkable 138% year-on-year surge...

AstraZeneca invests US$20M to curb Malaysia chronic disease burden

AstraZeneca is scaling up early screening and clinical research efforts in Malaysia as the...

AstraZeneca expands diagnostics and AI to tackle late-stage cancer deaths

AstraZeneca is sharpening its long-term AstraZeneca cancer strategy with a combination of heavy research...

AstraZeneca deploys AI to cut drug timelines by 30% and boost survival

AstraZeneca is stepping up its investment in AI drug discovery to shorten treatment timelines...

More like this

Top Glove Q3 FY2026 Earnings Rise Despite Fluctuating Material Costs

Resilient Growth and Strategic Agility Top Glove Corporation has reported a remarkable 138% year-on-year surge...

AstraZeneca invests US$20M to curb Malaysia chronic disease burden

AstraZeneca is scaling up early screening and clinical research efforts in Malaysia as the...

AstraZeneca expands diagnostics and AI to tackle late-stage cancer deaths

AstraZeneca is sharpening its long-term AstraZeneca cancer strategy with a combination of heavy research...